Show simple item record

dc.contributor.authorMoreno, V.
dc.contributor.authorBarretina-Ginesta, M. P.
dc.contributor.authorGarcía-Donas, J.
dc.contributor.authorJayson, Gordon C
dc.contributor.authorRoxburgh, P.
dc.contributor.authorVázquez, R. M.
dc.contributor.authorMichael, A.
dc.contributor.authorAntón-Torres, A.
dc.contributor.authorBrown, R.
dc.contributor.authorKrige, D.
dc.contributor.authorChampion, B.
dc.contributor.authorMcNeish, I.
dc.date.accessioned2022-01-11T12:00:08Z
dc.date.available2022-01-11T12:00:08Z
dc.date.issued2021en
dc.identifier.citationMoreno V, Barretina-Ginesta M-P, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial Vol. 9, Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. e003645.en
dc.identifier.pmid34893524en
dc.identifier.doi10.1136/jitc-2021-003645en
dc.identifier.urihttp://hdl.handle.net/10541/624962
dc.titleSafety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trialen
dc.typeArticleen
dc.contributor.departmentSTART Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spainen
dc.identifier.journalJournal for Immunotherapy of Canceren
dc.description.noteen]
refterms.dateFOA2022-04-12T10:12:56Z


Files in this item

Thumbnail
Name:
34893524.pdf
Size:
1.982Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record